Our findings suggest that ARX inhibition may contribute to redifferentiation of expanded human BCD cells, as part of an approach for β-cell replacement therapy of diabetes based on ex-vivo expansion of islet cells from individual donors for transplantation into multiple recipients. The gene discussed is ARX; the disease is diabetes mellitus.